Figure 3
Analysis of the tumor mutation burden in plasma circulating tumor DNA by CAPP-Seq. Tumor mutation burden in nine patients before and 4 weeks after afatinib treatment, and at the development of disease progression (A–I).
Figure 3 | Scientific Reports
